Correlation of human papillomavirus infection and clinical parameters with five-year survival in oral squamous cell carcinoma.
CONCLUSION: There is a high prevalence of HPV positive oral squamous cell carcinoma in Pakistan; however, there is no difference in the five-year survival rate when compared to HPV negative oral squamous cell carcinoma. PMID: 29888686 [PubMed - as supplied by publisher]
This study evaluated the integration and methlyation of human papillomavirus type 16 (HPV16) in head and neck squamous cell carcinoma (HNSCC) and its oral precursor, high-grade oral epithelial dysplasia (hgOED). Archival samples of HPV16-positive hgOED (N = 19) and HNSCC (N = 15) were evaluated, along with three HNSCC (UMSCC-1, -47 and -104) and two cervical cancer (SiHa and CaSki) cell lines. HgOED cases were stratified into three groups with increasing degrees of cytologic changes (mitosis, karyorrhexis and apoptosis). The viral load was higher and the E2/E6 ratio lower (indicating a greater tendency toward viral integra...
Over the last two decades, human papillomavirus related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) has been recognized as a fundamentally different disease than tobacco and alcohol related (HPV −) OPSSC [1–3]. While both diseases are squamous cell carcinomas that arise in the oropharynx, HPV+ disease tends to affect a younger cohort of patients with a different set of risk factors [1–3], and has been shown to have different molecular biology than HPV negative disease . Importantly , patients with HPV+ disease have a substantially improved prognosis [1–3,5].
This report describes a case of p16-positive tonsillar SCCa with metastasis to a highly unusual seconda ry site in the pleura to show an example of the unconventional patterns of distant metastases reported for HPV-positive oropharyngeal SCCa in the recent literature.
ConclusionSubstantial increase in awareness is required among OHP regarding HPV-OSCC link.
Conditions: Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma; Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Interventions: Drug: Cyclophosphamide; Biological: IRX-2; Biological: Nivolumab; Procedure: Surgery Sponsors: Emory University; Bristol-Myers Squibb; IRX Therapeutics Not yet recruiting